Previous 10 | Next 10 |
Combined Company Pro Forma 2019 Net Product Sales of Approximately $128 Million 1 Expects to Capture Significant Operating and Product Portfolio Synergies Upwards of $40 Million, Accelerating Revenue Growth and Creating Shareholder Value Arthur Higgins to Become the Non-Executive...
LAKE FOREST, Ill., March 11, 2020 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), today announces that it has commenced cash tender offers (the “Offers”) to purchase any and all of the outstanding $42,46...
Assertio Therapeutics, Inc. (ASRT) Q4 2019 Earnings Conference Call March 06, 2020, 04:30 PM ET Company Participants Arthur Higgins - President & CEO Dan Peisert - SVP & CFO Conference Call Participants Presentation Operator Good afternoon ladies and gentlemen...
The following slide deck was published by Assertio Therapeutics, Inc. in conjunction with their 2019 Q4 earnings Read more ...
Assertio Therapeutics (NASDAQ: ASRT ) Q4 results : More news on: Assertio Therapeutics, Inc., Healthcare stocks news, Earnings news and commentary, , Read more ...
Assertio Therapeutics (NASDAQ: ASRT ): Q4 EPS of -$0.14 may not be comparable to consensus of $0.14. More news on: Assertio Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
-- Reports Neurology Franchise Annual Net Sales of $108.1 Million, Exceeding Upper End of Prior Guidance -- -- Completed Strategic Asset Sales of NUCYNTA ® Franchise and Gralise ® Totaling $502.5 Million -- -- Repaid in Full Senior Secured Debt and Re...
LAKE FOREST, Ill., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (“Assertio” or “The Company”) (NASDAQ: ASRT), today announced it has entered into separate, privately negotiated agreements (the “Purchase Agreements”) with a limited n...
Image Source: ePainAssist Company Thesis A recent buyout of Assertio Therapeutics' ( ASRT ) pain relief drug Nucynta by Collegium Pharmaceutical ( COLL ) for $375M will erase all of ASRT's long term debt and convertible notes off its balance sheet. Combined with another $127.5M deal to...
LAKE FOREST, Ill., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (“Assertio” or “The Company”) (NASDAQ: ASRT), today announced the closing of its previously disclosed definitive agreement (“Agreement”) with Collegium Pharmaceutical, ...
News, Short Squeeze, Breakout and More Instantly...
Assertio Therapeutics Inc. Company Name:
ASRT Stock Symbol:
NASDAQ Market:
Assertio Therapeutics Inc. Website:
LAKE FOREST, Ill., July 24, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that it will rel...
2024-07-03 07:15:03 ET H.C. Wainwright analyst issues BUY recommendation for ASRT on July 3, 2024 06:04AM ET. ASRT was trading at $1.15 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recommendati...
LAKE FOREST, Ill., June 05, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced that Ajay Patel, Chief...